Riyue Bao

Riyue Bao

Auto-generated profile, based on publicly available information

Riyue Bao

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2018 in Science
Verified
Journal Article
Closed access
PDF file
VMVyara Matson
Vyara Matson
JFJessica Fessler
Jessica Fessler
RBRiyue Bao
Riyue Bao
TCTara Chongsuwat
Tara Chongsuwat
YZYuanyuan Zha
Yuanyuan Zha
TGThomas F. Gajewski
Thomas F. Gajewski
Good bacteria help fight cancer: Resident gut bacteria can affect patient responses to cancer immunotherapy (see the Perspective by Jobin). Routyet al.show that antibiotic consumption is associated with poor response to immunotherapeutic PD-1 blockade. They profiled samples from patients with lung and kidney cancers and found that nonresponding patients had low levels of the bacteriumAkkermansia muciniphila. Oral supplementation of the bacteria to antibiotic-treated mice restored the response to immunotherapy. Matsonet al.and Gopalakrishnanet al.studied melanoma patients receiving PD-1 blockade and found a greater abundance of “good” bacteria in the guts of responding patients. Nonresponders had an imbalance in gut flora composition, which correlated with impaired immune cell activity. Thus, maintaining healthy gut flora could help patients combat cancer.Science, this issue p.91, p.104, p.97; see also p.32

14 January 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
TFTaylor Feehley
Taylor Feehley
CPCatherine H. Plunkett
Catherine H. Plunkett
RBRiyue Bao
Riyue Bao
SHSung Min Choi Hong
Sung Min Choi Hong
ECElliot Culleen
Elliot Culleen
CNCathryn R. Nagler
Cathryn R. Nagler

8 February 2022 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
RARyan C. Augustin
Ryan C. Augustin
RLRobert D. Leone
Robert D. Leone
ANAung Naing
Aung Naing
LFLawrence Fong
Lawrence Fong
RBRiyue Bao
Riyue Bao
JLJason Luke
Jason Luke
Increasing evidence supports targeting the adenosine pathway in immuno-oncology with several clinical programs directed at adenosine A2 receptor (A2AR, A2BR), CD73 and CD39 in development. Through a cyclic-AMP-mediated intracellular cascade, adenosine shifts the cytokine and cellular profile of the tumor microenvironment away from cytotoxic T cell inflammation toward one of immune tolerance. A perpetuating cycle of tumor cell proliferation, tissue injury, dysregulated angiogenesis, and hypoxia promote adenosine accumulation via ATP catabolism. Adenosine receptor (eg, A2AR, A2BR) stimulation of both the innate and adaptive cellular precursors lead to immunosuppressive phenotypic differentiation. Preclinical work in various tumor models with adenosine receptor inhibition has demonstrated restoration of immune cell function and tumor regression. Given the broad activity but known limitations of anti-programmed cell death protein (PD1) therapy and other checkpoint inhibitors, ongoing studies have sought to augment the successful outcomes of anti-PD1 therapy with combinatorial approaches, particularly adenosine signaling blockade. Preliminary data have demonstrated an optimal safety profile and enhanced overall response rates in several early phase clinical trials with A2AR and more recently CD73 inhibitors. However, beneficial outcomes for both monotherapy and combinations have been mostly lower than expected based on preclinical studies, indicating a need for more nuanced patient selection or biomarker integration that might predict and optimize patient outcomes. In the context of known immuno-oncology biomarkers such as tumor mutational burden and interferon-associated gene expression, a comparison of adenosine-related gene signatures associated with clinical response indicates an underlying biology related to immunosuppression, angiogenesis, and T cell inflammation. Importantly, though, adenosine associated gene expression may point to a unique intratumoral phenotype independent from IFN-γ related pathways. Here, we discuss the cellular and molecular mechanisms of adenosine-mediated immunosuppression, preclinical investigation of adenosine signaling blockade, recent response data from clinical trials with A2AR, CD73, CD39 and PD1/L1 inhibitors, and ongoing development of predictive gene signatures to enhance combinatorial immune-based therapies.

19 January 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
RBRiyue Bao
Riyue Bao
LHLauren A. Hesser
Lauren A. Hesser
ZHZiyuan He
Ziyuan He
XZXiaoying Zhou
Xiaoying Zhou
KNKari C. Nadeau
Kari C. Nadeau
CNCathryn R. Nagler
Cathryn R. Nagler
BACKGROUND. There has been a striking generational increase in the prevalence of food allergies. We have proposed that this increase can be explained, in part, by alterations in the commensal microbiome. METHODS. To identify bacterial signatures and metabolic pathways that may influence the expression of this disease, we collected fecal samples from a unique, well-controlled cohort of twins concordant or discordant for food allergy. Samples were analyzed by integrating 16S rRNA gene amplicon sequencing and liquid chromatography–tandem mass spectrometry metabolite profiling. RESULTS. A bacterial signature of 64 operational taxonomic units (OTUs) distinguished healthy from allergic twins; the OTUs enriched in the healthy twins were largely taxa from the Clostridia class. We detected significant enrichment in distinct metabolite pathways in each group. The enrichment of diacylglycerol in healthy twins is of particular interest for its potential as a readily measurable fecal biomarker of health. In addition, an integrated microbial-metabolomic analysis identified a significant association between healthy twins and Phascolarctobacterium faecium and Ruminococcus bromii, suggesting new possibilities for the development of live microbiome-modulating biotherapeutics. CONCLUSION. Twin pairs exhibited significant differences in their fecal microbiomes and metabolomes through adulthood, suggesting that the gut microbiota may play a protective role in patients with food allergies beyond the infant stage. TRIAL REGISTRATION. Participants in this study were recruited as part of an observational study (ClinicalTrials.gov NCT01613885) at multiple sites from 2014 to 2018. FUNDING. This work was supported by the Sunshine Charitable Foundation; the Moss Family Foundation; the National Institute of Allergy and Infectious Diseases (NIAID) (R56AI134923 and R01AI 140134); the Sean N. Parker Center for Allergy and Asthma Research; the National Heart, Lung, and Blood Institute (R01 HL 118612); the Orsak family; the Kepner family; and the Stanford Institute for Immunity, Transplant and Infection.

24 April 2024 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
MHMeenakshi Hegde
Meenakshi Hegde
SNShoba Navai
Shoba Navai
CDChristopher DeRenzo
Christopher DeRenzo
SJSujith K. Joseph
Sujith K. Joseph
KSKhaled Sanber
Khaled Sanber
NANabil Ahmed
Nabil Ahmed

7 February 2023 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
RARyan C. Augustin
Ryan C. Augustin
RBRiyue Bao
Riyue Bao
JLJason Luke
Jason Luke
Cancer immunotherapy with immune-checkpoint blockade has improved the outcomes of patients with various malignancies, yet a majority do not benefit or develop resistance. To address this unmet need, efforts across the field are targeting additional coinhibitory receptors, costimulatory proteins, and intracellular mediators that could prevent or bypass anti-PD1 resistance mechanisms. The CD28 costimulatory pathway is necessary for antigen-specific T cell activation, though prior CD28 agonists did not translate successfully to clinic due to toxicity. Casitas B lymphoma-b (Cbl-b) is a downstream, master regulator of both CD28 and CTLA-4 signaling. This E3 ubiquitin ligase regulates both innate and adaptive immune cells, ultimately promoting an immunosuppressive tumor microenvironment (TME) in the absence of CD28 costimulation. Recent advances in pharmaceutical screening and computational biology have enabled the development of novel platforms to target this once ‘undruggable’ protein. These platforms include DNA encoded library screening, allosteric drug targeting, small-interfering RNA inhibition, CRISPR genome editing, and adoptive cell therapy. Both genetic knock-out models and Cbl-b inhibitors have been shown to reverse immunosuppression in the TME, stimulate cytotoxic T cell activity, and promote tumor regression, findings augmented with PD1 blockade in experimental models. In translating Cbl-b inhibitors to clinic, we propose specific gene expression profiles that may identify patient populations most likely to benefit. Overall, novel Cbl-b inhibitors provide antigen-specific immune stimulation and are a promising therapeutic tool in the field of immuno-oncology.